Orphan Drug Designation Zoci Enhances Treatment Prospects for Pulmonary Neuroendocrine Carcinomas

The European Medicines Agency has granted orphan drug designation for zocilurtatug pelitecan, an investigational DLL3-targeted antibody-drug conjugate, based on preliminary evidence of durable responses in relapsed or refractory extensive-stage small cell lung cancer.

Early trial data showed responses of extended duration that exceeded approved therapies in pretreated patients, prompting the Committee for Orphan Medicinal Products to recognize a clinically relevant advantage.

Seriousness and Unmet Need Confirmed

Orphan drug designation for zoci reflects both the aggressive nature of pulmonary neuroendocrine carcinomas and the lack of satisfactory treatments for the majority of patients facing this devastating diagnosis.

Small cell lung cancer, the predominant pulmonary neuroendocrine carcinoma, accounts for roughly 15 percent of the 2.5 million new lung cancer cases diagnosed globally each year, creating a substantial population with poor outcomes and limited therapeutic progress.

Regulatory Incentives Accelerate Next Steps

Orphan drug designation for zoci unlocks market exclusivity, fee reductions, and procedural efficiencies that will help expedite Zai Lab’s three planned registration-enabling studies across second-line, first-line small cell lung cancer, and extrapulmonary neuroendocrine carcinomas.